Abstract

Pharmaceuticals in the Environment (PiE) are an increasingly recognised risk to the quality of surface water and groundwater. The noPILLS project contributed towards a better understanding of the complex system of processes and – probably more importantly – actors that influence the presence of pharmaceutical micropollutants in waste water and, ultimately, receiving waters.
Clearly, a problem as complex and wide-ranging as that of pharmaceuticals in the aquatic environment cannot be comprehensively explored by a single project. However, noPILLS aimed to provide a unique insight into the problem by first defining the range of factors affecting pharmaceuticals in the environment, together with related points for intervention, and then investigating these interventions in a multi- and inter-disciplinary fashion.
In developing the concept of a “medicinal product chain” (of processes and actors), noPILLS identified potential “levers for intervention” towards the reduction of pharmaceutical ingress into the aquatic environment.
This report describes a series of case studies of applied investigative nature along the medicinal product chain, which explored and evaluated a range of levers for intervention for their underlying efficacy, efficiency, barriers and challenges.
In summary, the noPILLS project has shown that:
• Pharmaceutical micropollutants are ubiquitous in the aquatic environment in the project areas, and contribute to environmental effects;
• Regional differences exist in environmental conditions, as can be expected due to macro-geographical influences (landscape, climate etc), but conditions can also vary within regions and in time, with the biggest factors being influx of effluents and dilution in the environment;
• A risk highlighted by noPILLS is that of antibiotic resistance developing in - or being introduced into - the aquatic environment via the sewerage network;
• People, acting both as consumers/patients and as professionals, play an important role in the medicinal product chain and need to be involved more in intervention activities;
• Strong regional differences exist in factors that are influenced by human behaviour, attitudes, and awareness; most likely this is primarily a result of regional differences in systems (e.g. health system, funding, waste management);
• There appears to be a relatively high level of underlying willingness to ‘do the right thing’ both by the general public and professionals, which is largely under-utilized due to lack of information, support or means to change behaviour;
• Technological interventions are effective in reducing some pharmaceutical micropollutants but present their own challenges in terms of monetary and energy costs;
• Training, education and awareness raising, together with good stakeholder management and effective communication, are crucial for the success of all forms of intervention.
• There appears to be no single ‘silver bullet’ intervention point, and the whole medicinal product chain needs to be considered for multi-point, targeted intervention.
Original languageEnglish
PublisherEuropean Commission
Commissioning bodyEuropean Commission
Number of pages134
Publication statusPublished - May 2015

Fingerprint

drug
aquatic environment
water
human behavior
antibiotic resistance
education and training
environmental effect
waste management
stakeholder
dilution
environmental conditions
communication
effluent
surface water
groundwater
project
product
climate
cost
energy

Keywords

  • water contamination
  • toxicity assessment
  • wastewater
  • pharmaceutical residues
  • pharmaceuticals
  • data visualisation
  • wastewater treatment
  • 3D simulation

Cite this

Pahl, O., Casellas, M., Craft, J., Teedon, P., Klepiszewski , K., MacLachlan, J., ... Hunter, C. (2015). noPILLS in waters. European Commission.
Pahl, Ole ; Casellas, Megali ; Craft, John ; Teedon, Paul ; Klepiszewski , Kai ; MacLachlan, John ; Charissis, Vassilis ; Jiang, Jia-Qian ; McNaughtan, Moyra ; Hunter, Colin. / noPILLS in waters. European Commission, 2015. 134 p.
@book{eacb9dbb85df46b9b923ed7bbccbaeaf,
title = "noPILLS in waters",
abstract = "Pharmaceuticals in the Environment (PiE) are an increasingly recognised risk to the quality of surface water and groundwater. The noPILLS project contributed towards a better understanding of the complex system of processes and – probably more importantly – actors that influence the presence of pharmaceutical micropollutants in waste water and, ultimately, receiving waters.Clearly, a problem as complex and wide-ranging as that of pharmaceuticals in the aquatic environment cannot be comprehensively explored by a single project. However, noPILLS aimed to provide a unique insight into the problem by first defining the range of factors affecting pharmaceuticals in the environment, together with related points for intervention, and then investigating these interventions in a multi- and inter-disciplinary fashion. In developing the concept of a “medicinal product chain” (of processes and actors), noPILLS identified potential “levers for intervention” towards the reduction of pharmaceutical ingress into the aquatic environment. This report describes a series of case studies of applied investigative nature along the medicinal product chain, which explored and evaluated a range of levers for intervention for their underlying efficacy, efficiency, barriers and challenges.In summary, the noPILLS project has shown that:• Pharmaceutical micropollutants are ubiquitous in the aquatic environment in the project areas, and contribute to environmental effects;• Regional differences exist in environmental conditions, as can be expected due to macro-geographical influences (landscape, climate etc), but conditions can also vary within regions and in time, with the biggest factors being influx of effluents and dilution in the environment;• A risk highlighted by noPILLS is that of antibiotic resistance developing in - or being introduced into - the aquatic environment via the sewerage network;• People, acting both as consumers/patients and as professionals, play an important role in the medicinal product chain and need to be involved more in intervention activities;• Strong regional differences exist in factors that are influenced by human behaviour, attitudes, and awareness; most likely this is primarily a result of regional differences in systems (e.g. health system, funding, waste management);• There appears to be a relatively high level of underlying willingness to ‘do the right thing’ both by the general public and professionals, which is largely under-utilized due to lack of information, support or means to change behaviour;• Technological interventions are effective in reducing some pharmaceutical micropollutants but present their own challenges in terms of monetary and energy costs;• Training, education and awareness raising, together with good stakeholder management and effective communication, are crucial for the success of all forms of intervention.• There appears to be no single ‘silver bullet’ intervention point, and the whole medicinal product chain needs to be considered for multi-point, targeted intervention.",
keywords = "water contamination, toxicity assessment , wastewater, pharmaceutical residues , pharmaceuticals, data visualisation, wastewater treatment, 3D simulation",
author = "Ole Pahl and Megali Casellas and John Craft and Paul Teedon and Kai Klepiszewski and John MacLachlan and Vassilis Charissis and Jia-Qian Jiang and Moyra McNaughtan and Colin Hunter",
note = "Link to noPills partnership webpage (funding information may contribute to commissioning body): http://www.no-pills.eu/?page_id=11 ST 03.03.17",
year = "2015",
month = "5",
language = "English",
publisher = "European Commission",

}

Pahl, O, Casellas, M, Craft, J, Teedon, P, Klepiszewski , K, MacLachlan, J, Charissis, V, Jiang, J-Q, McNaughtan, M & Hunter, C 2015, noPILLS in waters. European Commission.

noPILLS in waters. / Pahl, Ole; Casellas, Megali; Craft, John; Teedon, Paul; Klepiszewski , Kai; MacLachlan, John; Charissis, Vassilis; Jiang, Jia-Qian; McNaughtan, Moyra; Hunter, Colin.

European Commission, 2015. 134 p.

Research output: Book/ReportCommissioned report

TY - BOOK

T1 - noPILLS in waters

AU - Pahl, Ole

AU - Casellas, Megali

AU - Craft, John

AU - Teedon, Paul

AU - Klepiszewski , Kai

AU - MacLachlan, John

AU - Charissis, Vassilis

AU - Jiang, Jia-Qian

AU - McNaughtan, Moyra

AU - Hunter, Colin

N1 - Link to noPills partnership webpage (funding information may contribute to commissioning body): http://www.no-pills.eu/?page_id=11 ST 03.03.17

PY - 2015/5

Y1 - 2015/5

N2 - Pharmaceuticals in the Environment (PiE) are an increasingly recognised risk to the quality of surface water and groundwater. The noPILLS project contributed towards a better understanding of the complex system of processes and – probably more importantly – actors that influence the presence of pharmaceutical micropollutants in waste water and, ultimately, receiving waters.Clearly, a problem as complex and wide-ranging as that of pharmaceuticals in the aquatic environment cannot be comprehensively explored by a single project. However, noPILLS aimed to provide a unique insight into the problem by first defining the range of factors affecting pharmaceuticals in the environment, together with related points for intervention, and then investigating these interventions in a multi- and inter-disciplinary fashion. In developing the concept of a “medicinal product chain” (of processes and actors), noPILLS identified potential “levers for intervention” towards the reduction of pharmaceutical ingress into the aquatic environment. This report describes a series of case studies of applied investigative nature along the medicinal product chain, which explored and evaluated a range of levers for intervention for their underlying efficacy, efficiency, barriers and challenges.In summary, the noPILLS project has shown that:• Pharmaceutical micropollutants are ubiquitous in the aquatic environment in the project areas, and contribute to environmental effects;• Regional differences exist in environmental conditions, as can be expected due to macro-geographical influences (landscape, climate etc), but conditions can also vary within regions and in time, with the biggest factors being influx of effluents and dilution in the environment;• A risk highlighted by noPILLS is that of antibiotic resistance developing in - or being introduced into - the aquatic environment via the sewerage network;• People, acting both as consumers/patients and as professionals, play an important role in the medicinal product chain and need to be involved more in intervention activities;• Strong regional differences exist in factors that are influenced by human behaviour, attitudes, and awareness; most likely this is primarily a result of regional differences in systems (e.g. health system, funding, waste management);• There appears to be a relatively high level of underlying willingness to ‘do the right thing’ both by the general public and professionals, which is largely under-utilized due to lack of information, support or means to change behaviour;• Technological interventions are effective in reducing some pharmaceutical micropollutants but present their own challenges in terms of monetary and energy costs;• Training, education and awareness raising, together with good stakeholder management and effective communication, are crucial for the success of all forms of intervention.• There appears to be no single ‘silver bullet’ intervention point, and the whole medicinal product chain needs to be considered for multi-point, targeted intervention.

AB - Pharmaceuticals in the Environment (PiE) are an increasingly recognised risk to the quality of surface water and groundwater. The noPILLS project contributed towards a better understanding of the complex system of processes and – probably more importantly – actors that influence the presence of pharmaceutical micropollutants in waste water and, ultimately, receiving waters.Clearly, a problem as complex and wide-ranging as that of pharmaceuticals in the aquatic environment cannot be comprehensively explored by a single project. However, noPILLS aimed to provide a unique insight into the problem by first defining the range of factors affecting pharmaceuticals in the environment, together with related points for intervention, and then investigating these interventions in a multi- and inter-disciplinary fashion. In developing the concept of a “medicinal product chain” (of processes and actors), noPILLS identified potential “levers for intervention” towards the reduction of pharmaceutical ingress into the aquatic environment. This report describes a series of case studies of applied investigative nature along the medicinal product chain, which explored and evaluated a range of levers for intervention for their underlying efficacy, efficiency, barriers and challenges.In summary, the noPILLS project has shown that:• Pharmaceutical micropollutants are ubiquitous in the aquatic environment in the project areas, and contribute to environmental effects;• Regional differences exist in environmental conditions, as can be expected due to macro-geographical influences (landscape, climate etc), but conditions can also vary within regions and in time, with the biggest factors being influx of effluents and dilution in the environment;• A risk highlighted by noPILLS is that of antibiotic resistance developing in - or being introduced into - the aquatic environment via the sewerage network;• People, acting both as consumers/patients and as professionals, play an important role in the medicinal product chain and need to be involved more in intervention activities;• Strong regional differences exist in factors that are influenced by human behaviour, attitudes, and awareness; most likely this is primarily a result of regional differences in systems (e.g. health system, funding, waste management);• There appears to be a relatively high level of underlying willingness to ‘do the right thing’ both by the general public and professionals, which is largely under-utilized due to lack of information, support or means to change behaviour;• Technological interventions are effective in reducing some pharmaceutical micropollutants but present their own challenges in terms of monetary and energy costs;• Training, education and awareness raising, together with good stakeholder management and effective communication, are crucial for the success of all forms of intervention.• There appears to be no single ‘silver bullet’ intervention point, and the whole medicinal product chain needs to be considered for multi-point, targeted intervention.

KW - water contamination

KW - toxicity assessment

KW - wastewater

KW - pharmaceutical residues

KW - pharmaceuticals

KW - data visualisation

KW - wastewater treatment

KW - 3D simulation

M3 - Commissioned report

BT - noPILLS in waters

PB - European Commission

ER -

Pahl O, Casellas M, Craft J, Teedon P, Klepiszewski K, MacLachlan J et al. noPILLS in waters. European Commission, 2015. 134 p.